Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report

Clin Ophthalmol. 2013:7:1089-92. doi: 10.2147/OPTH.S45155. Epub 2013 Jun 7.

Abstract

Introduction: The management of large pigment epithelial detachments (PEDs) associated with retinal angiomatous proliferation (RAP) remains a challenge due to the high risk of retinal pigment epithelial (RPE) tear. We describe the successful progressive anatomical result and the maintenance of visual acuity to bimonthly, half-dose ranibizumab in a patient with this condition.

Purpose: To describe the management of a large PED secondary to RAP with bimonthly, half-dose ranibizumab.

Method: Case report.

Patient: A 71-year-old woman presented with visual symptoms due to an enlarged PED, compared with previous visits, secondary to a RAP lesion, with a visual acuity of 20/32. To reduce the risk of an RPE tear and a significant decrease in vision, we discussed with the patient the possibility of treating the lesion in a progressive manner, with more frequent but smaller doses of ranibizumab. The patient was treated biweekly with 0.25 mg of ranibizumab until fattening of the PED.

Results: The large PED fattened progressively, and visual acuity was preserved with no adverse events.

Discussion: The use of half-dose antiangiogenic therapy may be useful in managing large vascularized PED associated with RAP, in an attempt to reduce the risk of RPE tear.

Keywords: RPE tear; age-related macular degeneration; pigment epithelial detachment; ranibizumab; retinal angiomatous proliferation.

Publication types

  • Case Reports